Ribonuclease (3.1.4) Patents (Class 435/199)
  • Patent number: 11987605
    Abstract: The present disclosure provides technologies for MYC inhibition, including, e.g. MYC fusion polypeptides and compositions comprising the same as well as methods of using the same. In particular, the present disclosure, among others, provides fusion polypeptides comprising a mutant MYC polypeptide and a repressor domain. In some embodiments, such fusion polypeptides and compositions comprising the same can be useful for inducing cancer cell apoptosis. Accordingly, in some embodiments, such fusion polypeptides and compositions comprising the same can be useful for cancer treatment.
    Type: Grant
    Filed: September 18, 2020
    Date of Patent: May 21, 2024
    Assignee: Helix Nanotechnologies Inc
    Inventors: Taylor Gill, Hannu Rajaniemi, Nikolai Eroshenko
  • Patent number: 11946052
    Abstract: The present disclosure relates to compositions of matter and assay methods used to detect one or more target nucleic acids of interest in a sample. The compositions and methods allow one to control reaction kinetics of the cascade assay by two orders of magnitude via molecular design of one of the reaction components; further, varying molecular design also allows for quantification of target nucleic acids of interest over a large range of concentrations or discriminating between extremely low copy numbers of target nucleic acids of interest.
    Type: Grant
    Filed: November 24, 2023
    Date of Patent: April 2, 2024
    Assignee: VedaBio, Inc.
    Inventors: Ariana Mostafa, Jacob Berger, Ashish Pandey, Anurup Ganguli
  • Patent number: 11897920
    Abstract: RVDs with recognition preferences for 5mC, 5hmC and 6 mA and different binding properties to these epigenetic modifications are identified in this present invention. Methylation-dependent gene activation, efficient genome editing, targeted detection of 5hmC and other applications can be achieved by using these RVDs. The present invention therefore provides an isolated DNA binding polypeptide containing TALEs, a fusion protein, a polynucleotide, a vector comprising the polynucleotide and a host cell, and the use of the protein comprising TALE repeats domain in the preparation of a reagent for detecting a methylated base in a target sequence of a gene of interest, as well as a method for targeting and binding to a target sequence of a gene of interest in a cell.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: February 13, 2024
    Assignees: Peking University, Edigene Inc.
    Inventors: Wensheng Wei, Chengqi Yi, Yuan Zhang, Shengjie Guo, Chenxu Zhu, Lulu Liu
  • Patent number: 11884922
    Abstract: The present disclosure relates to compositions of matter and assay methods used to detect one or more target nucleic acids of interest in a sample. The compositions and methods allow one to control reaction kinetics of the cascade assay by two orders of magnitude via molecular design of one of the reaction components; further, varying molecular design also allows for quantification of target nucleic acids of interest over a large range of concentrations or discriminating between extremely low copy numbers of target nucleic acids of interest.
    Type: Grant
    Filed: June 10, 2023
    Date of Patent: January 30, 2024
    Assignee: VedaBio, Inc.
    Inventors: Ariana Mostafa, Jacob Berger, Ashish Pandey, Anurup Ganguli
  • Patent number: 11859182
    Abstract: The present disclosure relates to compositions of matter and assay methods used to detect one or more target nucleic acids of interest in a sample. The compositions and methods allow one to control reaction kinetics of the cascade assay by two orders of magnitude via molecular design of one of the reaction components; further, varying molecular design also allows for quantification of target nucleic acids of interest over a large range of concentrations or discriminating between extremely low copy numbers of target nucleic acids of interest.
    Type: Grant
    Filed: May 31, 2023
    Date of Patent: January 2, 2024
    Assignee: VedaBio, Inc.
    Inventors: Anurup Ganguli, Ariana Mostafa, Jacob Berger, Ashish Pandey
  • Patent number: 11820983
    Abstract: The present disclosure relates to compositions of matter and assay methods used to detect one or more target nucleic acids of interest in a sample. The compositions and methods allow one to control reaction kinetics of the cascade assay by two orders of magnitude via molecular design of one of the reaction components; further, varying molecular design also allows for quantification of target nucleic acids of interest over a large range of concentrations or discriminating between extremely low copy numbers of target nucleic acids of interest.
    Type: Grant
    Filed: December 6, 2022
    Date of Patent: November 21, 2023
    Assignee: LabSimply, Inc.
    Inventors: Anurup Ganguli, Ariana Mostafa, Jacob Berger, Ashish Pandey
  • Patent number: 11692184
    Abstract: The present disclosure provides RNA-guided endonucleases, nucleic acids encoding same, and compositions comprising same. The present disclosure provides ribonucleoprotein complexes comprising: an RNA-guided endonuclease of the present disclosure; and a guide RNA. The present disclosure provides methods of modifying a target nucleic acid, using an RNA-guided endonuclease of the present disclosure and a guide RNA.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: July 4, 2023
    Assignee: The regents of the university of california
    Inventors: Nikos C. Kyrpides, Jennifer A. Doudna, Lucas Benjamin Harrington, David Paez-Espino
  • Patent number: 11572565
    Abstract: The technology described herein is directed to inducible and repressible polypeptides and polypeptide systems. In particular, described herein are split sequence-specific nucleases and split recombinases that are linked to drug-inducible or drug-repressible dimerization domains. In some embodiments, the polypeptides comprise sequestering domains and/or have their expression controlled by an inducible promoter. In multiple aspects described herein are polynucleotides, vectors, cells, and pharmaceutical compositions comprising said polypeptides or polypeptide systems. Also described herein are methods of using said polypeptide systems to modulate the expression of a target polypeptide or to treat a subject in need of a cell therapy.
    Type: Grant
    Filed: July 21, 2021
    Date of Patent: February 7, 2023
    Assignee: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Wilson Wai Chun Wong, Yage Ding
  • Patent number: 11499179
    Abstract: A cleavage-based real-time PCR assay method is provided. In general terms, the assay method includes subjecting a reaction mixture comprising a) PCR reagents for amplifying a nucleic acid target, and b) flap cleavage reagents for performing a flap cleavage assay on the amplified nucleic acid target to two sets of thermocycling conditions. No additional reagents are added to the reaction between said first and second sets of cycles and, in each cycle of the second set of cycles, cleavage of a flap probe is measured.
    Type: Grant
    Filed: February 12, 2020
    Date of Patent: November 15, 2022
    Assignee: Exact Sciences Development Company, LLC
    Inventors: Rebecca Oldham-Haltom, Hongzhi Zou, Graham P. Lidgard, Michael J. Domanico, Hatim Allawi
  • Patent number: 11390860
    Abstract: The present invention provides, for example, a set of two polypeptides exhibiting the nuclease activity with dependence on light or in the presence of a drug, in which an N-terminal side fragment and a C-terminal side fragment of a Cas9 protein are bound to each of two polypeptides which form a dimer with dependence on light or in the presence of a drug.
    Type: Grant
    Filed: April 13, 2016
    Date of Patent: July 19, 2022
    Assignee: The University of Tokyo
    Inventors: Moritoshi Sato, Yuta Nihongaki
  • Patent number: 11339408
    Abstract: The present disclosure provides a composition comprising a site-specific nuclease domain capable of cleaving a target DNA sequence; and a sequence-specific DNA binding domain capable of specifically binding to a recognition DNA sequence, wherein the site-specific nuclease domain operably links to the sequence-specific DNA binding domain.
    Type: Grant
    Filed: August 22, 2016
    Date of Patent: May 24, 2022
    Assignee: APPLIED STEMCELL, INC.
    Inventors: Ruby Yanru Tsai, Ling-jie Kong, Jingyuan Cao
  • Patent number: 11193131
    Abstract: Provided herein are materials and in planta methods for using haploid inducer lines containing a targeted endonuclease to generate transgenic or non-transgenic plants with targeted mutations and/or genomic modifications.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: December 7, 2021
    Assignee: Regents of the University of Minnesota
    Inventors: Benjamin W. Campbell, Junqi Liu, Robert M. Stupar
  • Patent number: 11193163
    Abstract: The present disclosure provides methods and systems for detecting nucleic acid sequences in a biological sample having a three-dimensional matrix. The present disclosure also provides methods and systems for processing a biological sample for use in nucleic acid sequence detection.
    Type: Grant
    Filed: November 6, 2019
    Date of Patent: December 7, 2021
    Assignee: ReadCoor, LLC
    Inventors: Evan Daugharthy, Richard Terry
  • Patent number: 11142584
    Abstract: The present invention provides CD20-binding proteins that bind to and rapidly internalize in a CD20-mediated fashion from a cell surface location to the interior of the cell. CD20-binding proteins of the invention comprise a CD20 binding region and a Shiga toxin effector region. Certain of the disclosed CD20-binding proteins kill cells that express CD20 on their surface. Further, the presently disclosed CD20-binding proteins can comprise additional exogenous materials, such as, e.g., antigens, and are capable of targeted delivery of these additional exogenous materials into the interior of CD20 expressing cells. These CD20-binding proteins have uses in methods such as, e.g.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: October 12, 2021
    Assignee: Molecular Templates, Inc.
    Inventors: Eric Poma, Jason Kim, Jack Higgins, Erin Willert, Sangeetha Rajagopalan
  • Patent number: 11111483
    Abstract: This disclosure provides various TcBuster transposases and transposons, systems, and methods of use.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: September 7, 2021
    Assignee: B-MoGen Biotechnologies, Inc.
    Inventors: David Largaespada, Branden Moriarity, Beau Webber, Neil Otto, Sandeep Kumar, Leah Hogdal
  • Patent number: 11078469
    Abstract: Engineered transcriptional activator-like effectors (TALEs) are versatile tools for genome manipulation with applications in research and clinical contexts. One current drawback of TALEs is that the 5? nucleotide of the target is specific for thymine (T). TALE domains with alternative 5? nucleotide specificities could expand the scope of DNA target sequences that can be bound by TALEs. Another drawback of TALEs is their tendency to bind and cleave off-target sequence, which hampers their clinical application and renders applications requiring high-fidelity binding unfeasible. This disclosure provides methods and strategies for the continuous evolution of proteins comprising DNA-binding domains, e.g., TALE domains. In some aspects, this disclosure provides methods and strategies for evolving such proteins under positive selection for a desired DNA-binding activity and/or under negative selection against one or more undesired (e.g., off-target) DNA-binding activities.
    Type: Grant
    Filed: February 28, 2020
    Date of Patent: August 3, 2021
    Assignee: President and Fellows of Harvard College
    Inventors: David R. Liu, Basil Hubbard, Ahmed Hussein Badran
  • Patent number: 10954559
    Abstract: Provided are an adaptor element in a bubble shape, a method of constructing a sequencing library with such an adapter element. The adaptor element is a hybrid formed with a long-chain nucleic acid A and a short-chain nucleic acid B. The hybrid is in the bubble shape with paired regions at two terminals and a non-paired region in the middle.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: March 23, 2021
    Assignee: MGI TECH CO., LTD.
    Inventors: Yuan Jiang, Xia Zhao, Qiaoling Li, Shengmao Liu, Bo Wang, Li Chen, Wenwei Zhang, Hui Jiang, Radoje Drmanac
  • Patent number: 10954497
    Abstract: The present invention relates to polypeptides, nucleotides encoding the polypeptide, as well as methods of producing the polypeptides. The present invention also relates to detergent composition comprising polypeptides, a laundering method and the use of polypeptides.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: March 23, 2021
    Assignee: NOVOZYMES A/S
    Inventors: Morten Gjermansen, Klaus Gori, Henrik Marcus Geertz-Hansen, Jesper Salomon, Thomas Holberg Blicher, Mary Ann Stringer, Nikolaj Spodsberg, Tianqi Sun
  • Patent number: 10947518
    Abstract: Proteases are enzymes which hydrolyze protein enzymes, eliminating their activity. The present invention exploits the hydrolyzing activity of proteases including proteinase K, endoproteinase LysC and/or trypsin to control the activity of restriction enzymes and/or eliminate or reduce production of unwanted DNA or RNA fragments (known as star activity).
    Type: Grant
    Filed: October 2, 2020
    Date of Patent: March 16, 2021
    Assignee: ABclonal Science, Inc.
    Inventors: Zhenyu Zhu, Dapeng Sun, Aine Quimby, Michaela Shottes
  • Patent number: 10888606
    Abstract: A peptide with anti-inflammatory activity is described, wherein the peptide comprises at least one amino acid sequence among SEQ ID NO: 2 to SEQ ID NO: 179, the peptide has above 80% homology of amino acid sequence with above-mentioned sequences, or the peptide is the fragment of the above-mentioned peptides. The peptides that have at least one amino acid sequence of SEQ ID NO: 2 to SEQ ID NO: 179 shows outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising those peptides can be used as anti-inflammatory pharmaceutical compositions or as cosmetic compositions, in turn, treating and preventing a variety of different types of inflammatory diseases.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: January 12, 2021
    Assignee: GEMVAX & KAEL CO., LTD.
    Inventors: Sang Jae Kim, Kyung Hee Kim, Kyu-Yong Lee, Seong-Ho Koh, Hyun-Hee Park, Sung Jin Huh, Woo Jin Lee, Bum Joon Kim
  • Patent number: 10851370
    Abstract: Disclosed herein are synthetic nucleic acids comprising a nucleic acid sequence that encodes a codon-Adapted Nuclear Argonaute protein (ANAGO) that is a species-specific to a eukaryote, and compositions comprising ANAGO and donor molecules for use in homologous recombination directed targeted gene editing in the eukaryote.
    Type: Grant
    Filed: August 29, 2019
    Date of Patent: December 1, 2020
    Assignee: PILLARGO, INC.
    Inventors: Ying Wu, Jiagang Zhao
  • Patent number: 10781472
    Abstract: The present invention relates in general to cellular analysis tools and more particularly to methods and systems for detecting or determining cyclic nucleotide concentrations and related pathway activation in samples. Samples containing cyclic nucleotides may be contacted with a cyclic nucleotide-dependent protein kinase (e.g., cAMP- and cGMP-dependent protein kinases) and a detection system that includes a substrate capable of being phosphorylated by the cyclic nucleotide-dependent protein kinase. The activity of cyclic nucleotide related cell signaling pathways may be measured based on detecting the activity of the cyclic nucleotide-dependent protein kinase.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: September 22, 2020
    Assignee: PROMEGA CORPORATION
    Inventors: Said A. Goueli, Kuei-Hsuan Hsiao, Meera Kumar, Jolanta Vidugiriene
  • Patent number: 10538556
    Abstract: Simple ?-hairpin peptides in linear and cyclic form that specifically bind to HIV-1 Trans-Activation Response element (HIV-1 TAR), as well as compositions and use thereof are described.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: January 21, 2020
    Assignees: Colorado State University Research Foundation, University of Rochester
    Inventors: Brian R. McNaughton, David W. Crawford, Joseph E. Wedekind, Ivan A. Belashov
  • Patent number: 10457968
    Abstract: The present invention provides improved DNA polymerases, in particular, type A DNA polymerases, that may be better suited for applications in recombinant DNA technologies. Among other things, the present invention provides modified DNA polymerases derived from directed evolution experiments designed to select mutations that confer advantageous phenotypes under conditions used in industrial or research applications.
    Type: Grant
    Filed: November 3, 2009
    Date of Patent: October 29, 2019
    Assignee: Kapa Biosystems, Inc.
    Inventors: William Bourn, Maryke Appel, Gavin Rush, John Foskett, Paul McEwan
  • Patent number: 10435679
    Abstract: Methods of making mutant Cas9 proteins are described.
    Type: Grant
    Filed: October 11, 2018
    Date of Patent: October 8, 2019
    Assignee: President and Fellows of Harvard College
    Inventors: Alejandro Chavez, Frank J. Poelwijk, George M. Church
  • Patent number: 10351831
    Abstract: Fusion polypeptides having a heterologous 5?-3? exonuclease domain linked to a polymerase that does not naturally have 5?-3? exonuclease activity, as well as methods of their use are provided. Other aspects are also disclosed.
    Type: Grant
    Filed: November 1, 2017
    Date of Patent: July 16, 2019
    Assignee: Bio-Rad Laboratories, Inc.
    Inventors: Yan Wang, Man Cheng
  • Patent number: 10323217
    Abstract: The disclosure concerns a detergent composition comprising one or more anionic surfactants; an enzyme selected from the group consisting of: a protease, a lipase, a cutinase, an amylase, a carbohydrase, a cellulase, a pectinase, a mannanase, an arabinase, a galactanase, a xylanase, and an oxidase; and a deoxyribonuclease (DNase), as well as methods for washing a textile.
    Type: Grant
    Filed: December 9, 2013
    Date of Patent: June 18, 2019
    Assignee: Novozymes A/S
    Inventors: Klaus Gori, Lilian Eva Tang Baltsen, Marie Allesen-Holm
  • Patent number: 10266851
    Abstract: Compositions and methods for using programmable DNA binding proteins to increase the efficiency and/or specificity of targeted genome modification or to facilitate the detection of specific genomic loci in eukaryotic cells.
    Type: Grant
    Filed: February 20, 2017
    Date of Patent: April 23, 2019
    Assignee: Sigma-Aldrich Co. LLC
    Inventor: Fuqiang Chen
  • Patent number: 10184121
    Abstract: Methods for screening pancrelipase for RNA virus contamination comprise removing free viral RNA from the pancrelipase, denaturing any viruses in the pancrelipase to release encapsidated RNA into the pancrelipase milieu, and detecting this released RNA. Removal of free viral RNA may comprise treating pancrelipase with RNase and DNase or precipitating the protein fraction of pancrelipase with a salt that precipitates the protein fraction while leaving nucleic acids such as RNA in solution. Pancrelipase substantially devoid of free nucleic acid is also provided.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: January 22, 2019
    Assignee: ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED
    Inventors: Giovanni Ortenzi, Luigi Ghidorsi
  • Patent number: 9952176
    Abstract: Apparatus and methods for size selecting nucleic acid molecules having wide range of applications including the production of DNA libraries for sequencing technologies. An automated high throughput system for size selection of multiple nucleic acid samples that uses imaging technique to detect the progress of a target fraction and feedback from the imaging to control electrophoresis. Predictive algorithms for timed nucleic acid extractions are generated to provide size selected nucleic acid molecules of required size ranges.
    Type: Grant
    Filed: June 15, 2012
    Date of Patent: April 24, 2018
    Assignee: British Columbia Cancer Agency Branch
    Inventors: Robin J. Noel Coope, Jared Raymond Slobodan
  • Patent number: 9856473
    Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of LMNA in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. Further provided are methods of identifying cis splicing regulatory elements of a selected mRNA using the disclosed compounds.
    Type: Grant
    Filed: June 25, 2014
    Date of Patent: January 2, 2018
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Kenneth W. Dobie, Susan M. Freier, Stanley T. Crooke, Timothy Vickers
  • Patent number: 9758796
    Abstract: The present invention is concerned with nuclease fusion proteins and various uses thereof. Specifically, it relates to a polynucleotide encoding a polypeptide comprising (i) a first module comprising at least a first DNA binding domain derived from a homing endonuclease, (ii) a linker, and (iii) a second module comprising at least a second DNA binding domain and a cleavage domain derived from a restriction endonuclease, wherein the polypeptide functionally interacts only with DNA comprising a DNA recognition site for the first DNA binding domain and a DNA recognition site for the second DNA binding domain, and wherein the cleavage domain cleaves DNA within a specific DNA cleavage site upon binding of the polypeptide. Further contemplated are a vector and a non-human transgenic organism comprising the polynucleotide as well as a polypeptide encoded by the polynucleotide of the invention.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: September 12, 2017
    Assignee: BASF PLANT SCIENCE COMPANY GMBH
    Inventors: Ines Fonfara, Wolfgang Wende, Alfred Pingoud
  • Patent number: 9675662
    Abstract: Compositions for inhibition of RNA Polymerase I include peptides of Rpa43. Methods of production and use thereof are also disclosed.
    Type: Grant
    Filed: December 2, 2011
    Date of Patent: June 13, 2017
    Assignee: The Board of Regents of the University of Oklahoma
    Inventor: Lawrence Rothblum
  • Patent number: 9567603
    Abstract: Methods for increasing specificity of RNA-guided genome editing, e.g., editing using CRISPR/Cas9 systems.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: February 14, 2017
    Assignee: The General Hospital Corporation
    Inventors: J. Keith Joung, Shengdar Tsai
  • Patent number: 9506110
    Abstract: A processing method to trim ends of DNA fragments, exposing the internal DNA part to give original DNA sequence information enabling application of next generation sequencing for DNA samples to be amplified by DOP-PCR or other primer dependent amplification methods. Specifically, nucleic acids are amplified using primers comprising a recognition site for a restriction enzyme, for example Bpml or Mmel. Primer sequences are removed by cleavage with the restriction enzyme.
    Type: Grant
    Filed: December 15, 2010
    Date of Patent: November 29, 2016
    Assignee: Agency for Science, Technology and Research
    Inventors: Masafumi Muratani, Huck Hui Ng
  • Patent number: 9491934
    Abstract: The present invention provides methods for modulating expression of endogenous cellular genes using recombinant zinc finger proteins.
    Type: Grant
    Filed: May 23, 2011
    Date of Patent: November 15, 2016
    Assignee: Sangamo BioSciences, Inc.
    Inventors: George Norbert Cox, III, Casey Christopher Case, Stephen P. Eisenberg, Eric Edward Jarvis, Sharon Kaye Spratt
  • Patent number: 9376689
    Abstract: Disclosed herein are engineered cleavage half-domains; fusion polypeptides comprising these engineered cleavage half-domains; polynucleotides encoding the engineered cleavage half-domains and fusion proteins; and cells comprising said polynucleotides and/or fusion proteins. Also described are methods of using these polypeptides and polynucleotides, for example for targeted cleavage of a genomic sequence.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: June 28, 2016
    Assignee: Sangamo BioSciences, Inc.
    Inventors: Yannick Doyon, Jeffrey C. Miller
  • Patent number: 9353358
    Abstract: The subject of the invention is the ribonuclease which cleaves RNA strand in DNA-RNA hybrids, wherein ribonuclease comprises fusion protein comprising catalytic domain of RNase HI (RNase HI) or derivative thereof with a zinc finger DNA-RNA hybrid binding domain, and wherein the zinc finger binding domain has the ability to bind to specific sequences in the DNA-RNA hybrid. The invention also relates to new methods for determination of the sequence preference of DNA-RNA hybrid binding protein(s) or its domain(s) and allows determining the sequence recognized by sequence specific binding protein in the DNA-RNA hybrid.
    Type: Grant
    Filed: December 3, 2013
    Date of Patent: May 31, 2016
    Assignee: MIEDZYNARODOWY INSTYTUT BIOLOGII MOLEKULARNEJ I KOMORKOWEJ
    Inventors: Janusz Marek Bujnicki, Agata Agnieszka Sulej, Krzysztof Jerzy Skowronek, Marcin Nowotny
  • Patent number: 9340835
    Abstract: The invention includes methods and apparatus for separating heteroduplexed nucleic acids from homoduplexed nucleic acids having similar sequences and being at a much higher concentration. The heteroduplexed nucleic acids may be separated through the application of a time varying driving field and a time-varying mobility field to a sample of heteroduplexed and homoduplexed nucleic acids in a separation medium. Once the heteroduplexed nucleic acids are isolated and recovered, it is straightforward to analyze the sequences of the heteroduplexed nucleic acids, e.g., using sequencing or hybrid assays.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: May 17, 2016
    Assignees: Boreal Genomics Corp., The University Of British Columbia
    Inventors: Andrea Marziali, Joel Pel
  • Patent number: 9217139
    Abstract: The purpose of the present invention is to provide a nuclease that secretes natural nonpathogenic microorganisms extracellularly, has higher specific activity than conventional nucleases, and is useful in nucleolytic degradation on an industrial scale. This purpose is achieved with an extracellularly secreted nuclease derived from Streptomyces bacteria, the nuclease having specific activity equal to or greater than the specific activity of Benzonase® when supplied to double-stranded DNA for 30 minutes at 37° C. in 20 mM Tris/HCl (pH 8.5) containing 1 mM MgCl2 and 1 mM CaCl2 after purification, using double-stranded DNA, single-stranded DNA, and RNA as substrates.
    Type: Grant
    Filed: September 15, 2011
    Date of Patent: December 22, 2015
    Assignee: JAPAN AGENCY FOR MARINE-EARTH SCIENCE AND TECHNOLOGY
    Inventors: Kozue Mori, Yukari Ohta, Yuji Hatada, Nobuyuki Nakamura, Masayuki Miyazaki
  • Patent number: 9200266
    Abstract: Disclosed herein are methods and compositions for generating a single-stranded break in a target sequence, which facilitates targeted integration of one or more exogenous sequences.
    Type: Grant
    Filed: March 6, 2014
    Date of Patent: December 1, 2015
    Assignee: Sangamo BioSciences, Inc.
    Inventor: Jianbin Wang
  • Patent number: 9034625
    Abstract: Compositions and methods are provided for enzymes with altered properties that involve a systematic approach to mutagenesis and a screening assay that permits selection of the desired proteins. Embodiments of the method are particularly suited for modifying specific properties of restriction endonucleases such as star activity. The compositions includes restriction endonucleases with reduced star activity as defined by an overall fidelity index improvement factor.
    Type: Grant
    Filed: January 8, 2013
    Date of Patent: May 19, 2015
    Assignee: New England Biolabs, Inc.
    Inventors: Zhenyu Zhu, Aine Quimby, Shuang-Yong Xu, Shengxi Guan, Hua Wei, Penghua Zhang, Dapeng Sun, Siu-hong Chan
  • Patent number: 9023634
    Abstract: Compositions and methods are provided for enzymes with altered properties that involve a systematic approach to mutagenesis and a screening assay that permits selection of the desired proteins. Embodiments of the method are particularly suited for modifying specific properties of restriction endonucleases such as star activity. The compositions includes restriction endonucleases with reduced star activity as defined by an overall fidelity index improvement factor.
    Type: Grant
    Filed: January 8, 2013
    Date of Patent: May 5, 2015
    Assignee: New England Biolabs, Inc.
    Inventors: Zhenyu Zhu, Aine Quimby, Shuang-Yong Xu, Shengxi Guan, Hua Wei, Penghua Zhang, Dapeng Sun, Siu-hong Chan
  • Publication number: 20150105315
    Abstract: The present invention relates to polypeptide fragments comprising an amino-terminal fragment of the PA subunit of a viral RNA-dependent RNA polymerase or variants thereof possessing endonuclease activity, wherein said PA subunit is from a virus belonging to the Orthomyxoviridae family. This invention also relates to (i) crystals of the polypeptide fragments which are suitable for structure determination of said polypeptide fragments using X-ray crystallography and (ii) computational methods using the structural coordinates of said polypeptide to screen for and design compounds that modulate, preferably inhibit the endonucleolytically active site within the polypeptide fragment. In addition, this invention relates to methods identifying compounds that bind to the PA polypeptide fragments possessing endonuclease activity and preferably inhibit said endonucleolytic activity, preferably in a high throughput setting.
    Type: Application
    Filed: October 21, 2014
    Publication date: April 16, 2015
    Applicants: EUROPEAN MOLECULAR BIOLOGY LABORATORY (EMBL), UNIVERSITY JOSEPH FOURIER FILIALE, Centre National de la Recherche Scientifique - Direction de la Politique Industrielle
    Inventors: Denis Bouvier, Thibaut Crepin, Rob Ruigrok, Alexander Dias, Stephen Cusack
  • Patent number: 9006407
    Abstract: The present invention relates to the use of ribonucleases (RNases) in the treatment or prevention of disease.
    Type: Grant
    Filed: January 7, 2014
    Date of Patent: April 14, 2015
    Assignee: Quintessence Biosciences, Inc.
    Inventors: Tony Klink, John Kink, Laura Strong
  • Publication number: 20150099290
    Abstract: Methods are provided for engineering non-naturally occurring proteins comprising artificial pH-sensitive conformational switches that respond to a change in pH by causing a global unfolding of the proteins. Non-naturally occurring proteins comprising artificial pH-sensitive conformational switches that respond to a change in pH by causing a global unfolding of the proteins are also provided.
    Type: Application
    Filed: October 6, 2014
    Publication date: April 9, 2015
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Bertrand E. Garcia-Moreno, Aaron Robinson
  • Patent number: 8999641
    Abstract: The invention provides for engineering and optimization of systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors with additional functional domains. Also provided are methods of directing CRISPR complex formation in prokaryotic and eukaryotic cells to ensure enhanced specificity for target recognition and avoidance of toxicity.
    Type: Grant
    Filed: March 26, 2014
    Date of Patent: April 7, 2015
    Assignees: The Broad Institute Inc., Maassachusetts Institute of Technology, President and Fellows of Harvard College
    Inventors: Feng Zhang, Le Cong, Randall Jeffrey Platt, Neville Espi Sanjana
  • Publication number: 20150093802
    Abstract: The present invention provides new zinc finger proteins and zinc finger nuclease (ZFNs) that find particular using in repairing the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
    Type: Application
    Filed: September 30, 2014
    Publication date: April 2, 2015
    Applicants: UNIVERSITY OF IOWA RESEARCH FOUNDATION, THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITAL
    Inventors: Paul MCCRAY, Morgan MAEDER, Jae Keith JOUNG
  • Publication number: 20150094209
    Abstract: The present invention provides autonomous replication sequences (ARSs) isolated from Nannochloropsis that support the replication of episomal DNA molecules (EDMs) in eukaryotic cells. The ARSs and EDMs provided herein can be used for expressing genes in organisms including algae and heterokonts.
    Type: Application
    Filed: December 6, 2013
    Publication date: April 2, 2015
    Applicant: Synthetic Genomics, Inc.
    Inventors: Peter DeHoff, Leah Soriaga, Srividya Akella
  • Patent number: 8993233
    Abstract: The invention provides for engineering and optimization of systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors with additional functional domains. Also provided are methods of directing CRISPR complex formation in prokaryotic and eukaryotic cells to ensure enhanced specificity for target recognition and avoidance of toxicity.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: March 31, 2015
    Assignees: The Broad Institute Inc., Massachusetts Institute of Technology, President and Fellows of Harvard College
    Inventors: Feng Zhang, Le Cong, Randall Jeffrey Platt, Neville Espi Sanjana, Fei Ran